Moreover, in contrast, treatment of GBM cell lines with the ML2-SA1 agonist impaired DOX sensitivity (IC50: from 47.0 to 95.0 and 3.5 to 5.6 μM, respectively). The gene discussed is STAG1; the disease is glioblastoma.